{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:44Z","timestamp":1790959364665,"version":"4.1.0"},"reference-count":11,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T00:00:00Z","timestamp":1519430400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2018,2,24]]},"DOI":"10.3233\/jhd-189001","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T09:09:25Z","timestamp":1519463365000},"page":"89-98","source":"Crossref","is-referenced-by-count":60,"title":["Huntington\u2019s Disease Clinical Trials Corner: February 2018"],"prefix":"10.1177","volume":"7","author":[{"given":"Filipe B.","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Huntington\u2019s Disease Centre, University College London, UK"},{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal"},{"name":"Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/JHD-189001_ref5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with huntington disease: A randomized clinical trial","volume":"316","author":"Huntington Study Group","year":"2016","journal-title":"Jama"},{"issue":"3","key":"10.3233\/JHD-189001_ref6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JHD-170262","article-title":"Clinical trials corner: September 2017","volume":"6","author":"Rodrigues","year":"2017","journal-title":"J Huntingtons Dis"},{"issue":"10","key":"10.3233\/JHD-189001_ref12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.3233\/JHD-189001_ref13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in huntington disease patients of european ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.3233\/JHD-189001_ref14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"issue":"9","key":"10.3233\/JHD-189001_ref15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nature biotechnology"},{"issue":"1","key":"10.3233\/JHD-189001_ref16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"Jama"},{"issue":"8","key":"10.3233\/JHD-189001_ref18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","article-title":"Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea","volume":"74","author":"Frank","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.3233\/JHD-189001_ref19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine versus deutetrabenazine for Huntington\u2019s disease: Twins or distant cousins?","volume":"4","author":"Rodrigues","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JHD-189001_ref20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J Clin Mov Disord"},{"issue":"9","key":"10.3233\/JHD-189001_ref21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40734-017-0067-x","article-title":"Meta-research metrics matter: Letter regarding article \u201cindirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease\u201d","volume":"4","author":"Rodrigues","year":"2017","journal-title":"J Clin Mov Disord"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-189001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:24Z","timestamp":1777453044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-189001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,24]]},"references-count":11,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-189001","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,24]]}}}